2016 | Volume Volume - 1 - Issue Issue - 1

In this issue

Research Article

Open Access Research Article PTZAID:IJICR-1-106

Anti-VEGF Therapy Induces Proteinuria through Endothelial Disorganization Leading to Nephrin Decrease in Podocytes

Published On: October 28, 2015 | Pages: 021 - 028

Author(s): Marianne Terrasse*, Florence Jouan, Thibault Dolley-Hitze, Yannick Arlot-Bonnemains, Marc-Antoine Belaud-Rotureau, Nathalie Rioux-Leclercq, Nolwenn Lorcy, Cécile Vigneau

Background: VEGF is involved in cancer development by stimulating neo-angiogenesis and tumor proliferation. Anti-angiogenic therapies, especially tyrosine kinase inhibitors such as sunitinib, have significantly improved cancer prognosis. Nevertheless, renal side effects, such as proteinuria and thrombotic microangiopathy, have been reported. The underlying physiopatho ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000006

Open Access Research Article PTZAID:IJICR-1-101

Adiponectin Regulates the Development and Progression of MCA-Induced Sarcoma in Mice

Published On: August 05, 2015 | Pages: 001 - 003

Author(s): Rongxin Zhang*, Kai Zhang, Xi Wu, Zhihui Zhang, Shuyu Fu, Yurong Da, Mei Mei, Qi Zhang, Yan Li, Zhenyi Xue, Lijuan Zhang, Peng Zhao

Background: Sarcomas are malignant tumors with low survival rates and remain refractory to the current therapeutic methods. Adiponectin plays crucial roles in many physiological responses. Studies have shown that adiponectin could regulate various tumors. However, the roles of adiponectin in sarcomas remain unknown. ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000001

Review Article

Open Access Review Article PTZAID:IJICR-1-105

Probiotics and Bone Health: It takes GUTS to Improve Bone Density

Published On: October 13, 2015 | Pages: 018 - 022

Author(s): Rupesh K Srivastava*, Hamid Yousf, Geetanjali B Tomar

Probiotics are a class of symbiotic bacteria whose administration in adequate amount provides health benefits to the host by altering the composition of gut microbiota. The gut microbiota is known to regulate both the host immune system and metabolism, leading to increased bone mass by inhibiting bone resorption. Ovariectomy induced estrogen deficiency which mimics po ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000005

Open Access Review Article PTZAID:IJICR-1-104

N-Methyl-D-Aspartate (NMDA) Receptors: Therapeutic Target against Cancer

Published On: September 03, 2015 | Pages: 013 - 017

Author(s): Raj Kumar Koiri*, Aditi Mehrotra

Glutamate (Glu) mainly acts as an excitatory neurotransmitter in the central nervous system controlling variety of neuro-physiological functions like synaptic signaling, learning, memory, etc. However, uncontrolled or excessive production of glutamate is neurotoxic and can damage neurons by over activation of glutamate receptors termed as “glutamate excitotoxicity”. A ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000004

Open Access Review Article PTZAID:IJICR-1-103

SMART Drug Based Targeted Delivery: A New Paradigm for Nanomedicine Strategies

Published On: August 20, 2015 | Pages: 008 - 012

Author(s): Sugapriya Dhanasekaran*

Introduction: Targeted drug delivery systems are nanoscale drug carrier molecules designed for improving the communication of cellular and molecular components and biodistribution of tumour targeted drug (chemo) therapeutics. Nanomaterials are generally clusters of molecules, atoms and molecular fragments into extremely small size particles (1-100 nm) in nature. Nanom ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000003

Case Report

Open Access Case Report PTZAID:IJICR-1-102

Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

Published On: August 14, 2015 | Pages: 004 - 007

Author(s): Romeo-Gabriel Mihaila*

Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeu ...

Abstract View Full Article View DOI: 10.17352/2455-8591.000002